Scholars Central

ArticlePublished 2009

Sirolimus Can Reverse Resistance to Gemcitabine, Capecitabine and Docetaxel Combination Therapy in Pancreatic Cancer

Authors: William H Sherman

Journal of the Pancreas

Volume 10 · Issue 4

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Context Treating patients with metastatic carcinoma of the pancreas can lead to regression of disease, but the tumor becomes resistant to therapy within a few months. If resistance can be reversed or prevented, the chemotherapeutic benefit may be prolonged. Case reports Two patients with metastatic pancreatic cancer progressed on gemcitabine, capecitabine and docetaxel (GTX). When sirolimus was added to this regimen at a dosage to achieve a serum level of at least 10 ng/dL at the time of the gemcitabine and docetaxel infusion, their tumors regressed. Conclusion This demonstrates that the addition of sirolimus to a gemcitabine/docetaxel containing regimen can reverse tumor resistance in the clinical setting.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of the Pancreas.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of the Pancreas
  • SubjectGastroenterology & Hepatology
  • BylineArticles whose byline prints “William H Sherman”